Back to GetFilings.com



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

Form 10-Q

 

ý

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2004

 

 

OR

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from                           to                          

 

 

Commission File No. 0-29608

 

GENETRONICS BIOMEDICAL CORPORATION

(Exact name of Registrant as specified in its charter)

 

Delaware

 

33-0969592

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

 

11199 SORRENTO VALLEY ROAD
SAN DIEGO, CALIFORNIA  92121-1334

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)(ZIP CODE)

 

 

 

(858) 597-6006

(COMPANY’S TELEPHONE NUMBER, INCLUDING AREA CODE)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ý    No  o

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý

 

The number of shares outstanding of the registrant’s Common Stock, par value $ 0.001 per share, was 70,015,334 as of April 30, 2004.

 

 



 

GENETRONICS BIOMEDICAL CORPORATION

 

FORM 10-Q

 

For the Quarter Ended March 31, 2004

 

INDEX

 

Part I. Financial Information

 

 

 

Item 1.  Financial Statements

 

 

 

 

 

 

a)

Consolidated Balance Sheets as of March 31, 2004 (Unaudited) and December 31, 2003

 

 

 

 

 

 

 

 

 

 

b)

Consolidated Statements of Operations for the Three Months Ended March 31, 2004 and 2003 (Unaudited)

 

 

 

 

 

 

 

 

 

 

c)

Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2004 and 2003 (Unaudited)

 

 

 

 

 

 

 

 

 

 

d)

Notes to Consolidated Financial Statements

 

 

 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

 

 

Item 4. Controls and Procedures

 

 

 

Part II. Other Information

 

 

 

Item 1. Legal Proceedings

 

 

 

Item 2. Changes in Securities and Use of Proceeds

 

 

 

Item 3. Defaults Upon Senior Securities

 

 

 

Item 4. Submission of Matters to a Vote of Security Holders

 

 

 

Item 5. Other Information

 

 

 

Item 6. Exhibits and Reports on Form 8-K

 

 

 

Signatures

 

 



 

Part I. Financial Information

 

Item 1. Financial Statements

 

GENETRONICS BIOMEDICAL CORPORATION

 

CONSOLIDATED BALANCE SHEETS

 

 

 

March 31,
2004

 

December 31,
2003

 

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

Current

 

 

 

 

 

Cash and cash equivalents

 

$

13,128,944

 

$

13,460,446

 

Receivables, net

 

7,200

 

175,000

 

Prepaid expenses and other

 

80,755

 

116,526

 

Total current assets

 

13,216,899

 

13,751,972

 

Fixed assets, net

 

152,829

 

175,902

 

Patents and other assets, net

 

2,314,831

 

2,301,116

 

Total assets

 

$

15,684,559

 

$

16,228,990

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current

 

 

 

 

 

Accounts payable and accrued expenses

 

$

554,798

 

$

827,655

 

Deferred revenue

 

268,979

 

331,164

 

Total current liabilities

 

823,777

 

1,158,819

 

Deferred rent

 

16,389

 

22,536

 

Total liabilities

 

840,166

 

1,181,355

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

Preferred stock, $0.001 par value

 

1

 

1

 

Common stock, $0.001 par value

 

69,687

 

63,682

 

Additional paid in capital

 

92,656,461

 

91,185,936

 

Accumulated deficit

 

(77,881,756

)

(76,201,984

)

Total stockholders’ equity

 

14,844,393

 

15,047,635

 

Total liabilities and stockholders’ equity

 

$

15,684,559

 

$

16,228,990

 

 

See accompanying notes

 

1



 

GENETRONICS BIOMEDICAL CORPORATION

 

CONSOLIDATED STATEMENTS OF
OPERATIONS

(Unaudited)

 

 

 

Three Months
Ended March 31,
2004

 

Three Months
Ended March 31,
2003

 

REVENUE

 

 

 

 

 

License fee and milestone payments

 

$

1,471

 

$

1,471

 

Revenues under collaborative research and development arrangement

 

67,914

 

9,666

 

Total revenue

 

69,385

 

11,137

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

Research and development

 

588,860

 

475,734

 

General and administrative

 

1,097,196

 

1,263,463

 

Interest (income) expense, net

 

(35,039

)

17,230

 

 

 

 

 

 

 

Total expenses

 

1,651,017

 

1,756,427

 

 

 

 

 

 

 

Loss from continuing operations

 

(1,581,632

)

(1,745,290

)

 

 

 

 

 

 

Discontinued operations:

 

 

 

 

 

Gain on disposal

 

 

2,034,078

 

Loss from operations

 

 

(110,740

)

Net (loss) income

 

(1,581,632

)

178,048

 

Declared dividends on preferred stock

 

(98,140

)

 

Net (loss) income attributable to common stockholders

 

$

(1,679,772

)

$

178,048

 

 

 

 

 

 

 

Amounts per common share – basic and diluted:

 

 

 

 

 

Loss from continuing operations

 

$

(0.03

)

$

(0.03

)

Income from discontinued operations

 

 

0.03

 

Declared dividends on preferred stock

 

 

 

Net loss per common share

 

$

(0.03

)

$

 

 

 

 

 

 

 

Weighted average number of common shares - basic

 

65,274,581

 

50,406,608

 

Weighted average number of common shares - diluted

 

65,274,581

 

50,632,087

 

 

See accompanying notes

 

2



 

GENETRONICS BIOMEDICAL CORPORATION

 

CONSOLIDATED STATEMENTS OF
CASH FLOWS

 

(Unaudited)